Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Oral tranexamic acid and thrombosis risk in women

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. GLP-1 based therapies and disease course of inflammatory bowel disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Successful glucose lowering therapy triumphs in heart failure

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  3. Implementation of indicator condition guided HIV testing still lagging behind the evidence

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Background: Oral tranexamic acid is effective for heavy menstrual bleeding, but the thrombosis risk with this treatment is largely not studied.

Methods: Using nationwide registries, we assessed associations between use of oral tranexamic acid and risk of deep-vein thrombosis or pulmonary embolism and arterial thrombosis in heart or brain in a nationwide historical prospective cohort of Danish women aged 15 to 49 years in the period 1996-2017. Exclusion criteria included potential confounding factors such as history of thromboembolism, anticoagulation therapy, thrombophilia, and cancer.

Findings: Among 2·0 million women followed for 13·8 million person-years, 3,392 venous thromboembolisms and 4,198 arterial thromboses occurred. A total of 63,896 women (3·2%) filled 146,729 prescriptions of oral tranexamic acid during follow-up with median filled prescription per user being one of 15 g. The age-standardised incidence rate of venous thromboembolism was 11·8 (95% CI 4·6 to 30·2) per 10,000 person-years in oral tranexamic acid use compared to 2·5 (2·4 to 2·6) per 10,000 person-years in non-use. For arterial thrombosis, the age-standardised incidence rate per 10,000 person-years was 3·4 (1·1 to 10·7) among exposed compared to 3·0 (2·9 to 3·1) in non-exposed. Comparing oral tranexamic acid use with non-use, the adjusted incidence rate ratio was 4·0 (1·8 to 8·8) for venous thromboembolism and 1·3 (0·4 to 4·2) for arterial thrombosis.Number needed to harm per five days of treatment was 78,549 women for venous thromboembolism.

Interpretation: We found use of oral tranexamic acid to be positively associated with venous thromboembolism. However, number needed to harm per five days of treatment was high.

OriginalsprogEngelsk
Artikelnummer100882
TidsskriftEClinicalMedicine
Vol/bind35
Sider (fra-til)100882
ISSN2589-5370
DOI
StatusUdgivet - maj 2021

Bibliografisk note

© 2021 The Author(s).

ID: 68135085